Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Covira logo — Modulating the Gut Microbiome to Prevent Post-Surgical Infec...

Covira

Modulating the Gut Microbiome to Prevent Post-Surgical Infections

Founded 2018 United States North Chicago, United States 6 employees Grant Biopharma, Biotechnology +1

General Information

Company Name Covira
Founded Year 2018
Location United States North Chicago, United States
Employees 6
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Covira. To contact Covira, visit covirasurgical.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Covira compare?

A PDF of Covira and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Covira soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Covira

Covira is an early-stage biotech company, a spinout from The University of Chicago (Sept 2018). This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira's focus is to develop drugs that work by modulating the biological activity of the gut microbiome's resident bacteria. Covira’s lead asset (CS-0003) is a platform technology that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. CS-0003 is transformative to the field and the world is taking notice...in the 4th quarter of last year Business Worldwide Magazine named Covira Among the 2021- Top 20 Most Innovative Companies to Watch.

No funding data available for Covira yet.

FAQ About Covira

Modulating the Gut Microbiome to Prevent Post-Surgical Infections
Covira was founded in 2018.
Covira is headquartered in North Chicago, United States.
Covira operates in Biopharma, Biotechnology and Life Sciences.
Covira has approximately 6 employees.

We're actively collecting intelligence on Covira.

Source: BounceWatch company record for Covira, https://bouncewatch.com/company/covira, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes